Parker C - Search Results

1

National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting.

Brizmohun Appayya M, Adshead J, Ahmed HU, Allen C, Bainbridge A, Barrett T, Giganti F, Graham J, Haslam P, Johnston EW, Kastner C, Kirkham APS, Lipton A, McNeill A, Moniz L, Moore CM, Nabi G, Padhani AR, Parker C, Patel A, Pursey J, Richenberg J, Staffurth J, van der Meulen J, Walls D, Punwani S. Brizmohun Appayya M, et al. Among authors: parker c. BJU Int. 2018 Jul;122(1):13-25. doi: 10.1111/bju.14361. Epub 2018 Jun 5. BJU Int. 2018. PMID: 29699001 Free PMC article.

2

Does age influence the behaviour of localized prostate cancer?

Parker CC, Gospodarowicz M, Warde P. Parker CC, et al. BJU Int. 2001 May;87(7):629-37. doi: 10.1046/j.1464-410x.2001.02141.x. BJU Int. 2001. PMID: 11350402

3

Management of early prostate cancer.

Horwich A, Parker CC, Huddart RA, Dearnaley DP. Horwich A, et al. Among authors: parker cc. Ann Oncol. 2002;13 Suppl 4:83-7. doi: 10.1093/annonc/mdf643. Ann Oncol. 2002. PMID: 12401671 Free article. Review. No abstract available.

4

Hormonal therapy as an adjuvant to radical radiotherapy for locally advanced prostate cancer.

Parker C, Dearnaley D. Parker C, et al. BJU Int. 2003 Jan;91(1):6-8. doi: 10.1046/j.1464-410x.2003.04008.x. BJU Int. 2003. PMID: 12614240 No abstract available.

5

Active surveillance: an individualized approach to early prostate cancer.

Parker C. Parker C. BJU Int. 2003 Jul;92(1):2-3. doi: 10.1046/j.1464-410x.2003.04295.x. BJU Int. 2003. PMID: 12823371 No abstract available.

6

Early outcomes of active surveillance for localized prostate cancer.

Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D. Hardie C, et al. Among authors: parker c. BJU Int. 2005 May;95(7):956-60. doi: 10.1111/j.1464-410X.2005.05446.x. BJU Int. 2005. PMID: 15839912

7

Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy.

Jackson AS, Parker CC, Norman AR, Padhani AR, Huddart RA, Horwich A, Husband JE, Dearnaley DP. Jackson AS, et al. Among authors: parker cc. Clin Oncol (R Coll Radiol). 2005 May;17(3):167-71. doi: 10.1016/j.clon.2004.08.007. Clin Oncol (R Coll Radiol). 2005. PMID: 15901000

8

Prolonging survival in prostate cancer: chemotherapy will have an important role.

Parker C, Emberton M. Parker C, et al. BJU Int. 2005 Jul;96(1):2-3. doi: 10.1111/j.1464-410X.2005.05554.x. BJU Int. 2005. PMID: 15963108 No abstract available.

9

The Scandinavian Prostate Cancer Group Study: the case for conservative management.

Parker C. Parker C. BJU Int. 2005 Nov;96(7):952-3. doi: 10.1111/j.1464-410X.2005.05794.x. BJU Int. 2005. PMID: 16225505 No abstract available.

10

Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy.

Jackson AS, Sohaib SA, Staffurth JN, Huddart RA, Parker CC, Horwich A, Dearnaley DP. Jackson AS, et al. Among authors: parker cc. Clin Oncol (R Coll Radiol). 2006 Mar;18(2):109-16. doi: 10.1016/j.clon.2005.09.006. Clin Oncol (R Coll Radiol). 2006. PMID: 16523810

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,100 results

Search Page